Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Fox

Showing results (21-30 of 69) with videos related to

Pageof 7
Sort By:
American Heart Journal|February 17, 2019
A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristicsRoberto Ferrari, Ian Ford, Kim Fox, et al.
International Journal of Cardiology|May 15, 2007
Differences in presentation and management of stable angina from East to West in Europe: a comparison between Poland and the UKCaroline Ann Daly, Janina Stepinska, Tomasz Deptuch, et al.
European Heart Journal|August 25, 2011
Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary interventionM Louisa Antoni, Helèn Boden, Victoria Delgado, et al.
International Journal of Cardiology|January 9, 2015
Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysisJasper J Brugts, Laura van Vark, Martijn Akkerhuis, et al.
Lancet (London, England)|September 3, 2020
Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trialRoberto Ferrari, Ian Ford, Kim Fox, et al.
The American Journal of Cardiology|January 21, 2011
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy)Michal Tendera, Mario Talajic, Michele Robertson, et al.
European Heart Journal|April 19, 2012
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patientsLaura C van Vark, Michel Bertrand, K Martijn Akkerhuis, et al.
Archivos De Cardiologia De Mexico|April 30, 2015
Heart rate and use of β-blockers in Mexican stable outpatients with coronary artery diseaseMarco Antonio Alcocer-Gamba, Carlos Martínez-Sánchez, Juan Verdejo-Paris, et al.
Open Heart|April 11, 2018
Role of ivabradine in management of stable angina in patients with different clinical profilesJuan Carlos Kaski, Steffen Gloekler, Roberto Ferrari, et al.
European Journal of Heart Failure|April 17, 2020
Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective CLARIFY registryZofia Parma, Adam Jasilek, Nicola Greenlaw, et al.
Pageof 7

Showing results (21-30 of 69) with videos related to

Sort By:
Pageof 7
American Heart Journal|February 17, 2019
A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristicsRoberto Ferrari, Ian Ford, Kim Fox, et al.
International Journal of Cardiology|May 15, 2007
Differences in presentation and management of stable angina from East to West in Europe: a comparison between Poland and the UKCaroline Ann Daly, Janina Stepinska, Tomasz Deptuch, et al.
European Heart Journal|August 25, 2011
Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary interventionM Louisa Antoni, Helèn Boden, Victoria Delgado, et al.
International Journal of Cardiology|January 9, 2015
Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysisJasper J Brugts, Laura van Vark, Martijn Akkerhuis, et al.
Lancet (London, England)|September 3, 2020
Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trialRoberto Ferrari, Ian Ford, Kim Fox, et al.
The American Journal of Cardiology|January 21, 2011
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy)Michal Tendera, Mario Talajic, Michele Robertson, et al.
European Heart Journal|April 19, 2012
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patientsLaura C van Vark, Michel Bertrand, K Martijn Akkerhuis, et al.
Archivos De Cardiologia De Mexico|April 30, 2015
Heart rate and use of β-blockers in Mexican stable outpatients with coronary artery diseaseMarco Antonio Alcocer-Gamba, Carlos Martínez-Sánchez, Juan Verdejo-Paris, et al.
Open Heart|April 11, 2018
Role of ivabradine in management of stable angina in patients with different clinical profilesJuan Carlos Kaski, Steffen Gloekler, Roberto Ferrari, et al.
European Journal of Heart Failure|April 17, 2020
Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective CLARIFY registryZofia Parma, Adam Jasilek, Nicola Greenlaw, et al.
Pageof 7